Drug intelligence / Profile preview

CJM112

Development stage: Phase 2
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

CJM112 is a human monoclonal antibody developed by Novartis that targets and neutralizes interleukin-17A (IL-17A) and interleukin-17AF (IL-17AF), key cytokines involved in inflammatory processes. By binding to these cytokines, CJM112 inhibits their activity and reduces inflammation. It has been investigated for the treatment of several immune-mediated diseases including moderate to severe plaque psoriasis, hidradenitis suppurativa, acne vulgaris, and asthma. Clinical studies have shown that it is generally safe and well tolerated at tested doses; however, its efficacy did not consistently surpass existing therapies such as secukinumab[1][2][7][9].

Other names: CJM112CJM-112CJM 112

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on CJM112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CJM112.

Explore the full profile